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Abstract 
Background: Mutations in the isocitrate dehydrogenase enzyme are present in a majority of lower-grade gliomas 
and secondary glioblastomas. This mis-sense mutation results in the neomorphic reduction of isocitrate dehydroge-
nase resulting in an accumulation of the “oncometabolite” 2-hydroxyglutarate (2HG). Detection of 2HG can thus serve 
as a surrogate biomarker for these mutations, with significant translational implications including improved prog-
nostication. Two dimensional localized correlated spectroscopy (2D L-COSY) at 7T is a highly-sensitive non-invasive 
technique for assessing brain metabolism. This study aims to assess tumor metabolism using 2D L-COSY at 7T for the 
detection of 2HG in IDH-mutant gliomas.
Methods: Nine treatment-naïve patients with suspected intracranial neoplasms were scanned at 7T MRI/MRS scan-
ner using the 2D L-COSY technique. 2D-spectral processing and analyses were performed using a MATLAB-based 
reconstruction algorithm. Cross and diagonal peak volumes were quantified in the 2D L-COSY spectra and normal-
ized with respect to the creatine peak at 3.0 ppm and quantified data were compared with previously-published data 
from six normal subjects. Detection of 2HG was validated using findings from immunohistochemical (IHC) staining in 
patients who subsequently underwent surgical resection.
Results: 2HG was detected in both of the IDH-mutated gliomas (grade III Anaplastic Astrocytoma and grade II Diffuse 
Astrocytoma) and was absent in IDH wild-type gliomas and in a patient with breast cancer metastases. 2D L-COSY was 
also able to resolve complex and overlapping resonances including phosphocholine (PC) from glycerophosphocho-
line (GPC), lactate (Lac) from lipids and glutamate (Glu) from glutamine (Gln).
Conclusions: This study demonstrates the ability of 2D L-COSY to unambiguously detect 2HG in addition to other 
neuro metabolites. These findings may aid in establishing 2HG as a biomarker of malignant progression as well as for 
disease monitoring in IDH-mutated gliomas.
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Background
Mutations in the gene encoding isocitrate dehydrogenase 
(IDH) occur in up to 80  % of World Health Organiza-
tion (WHO) grade II/III gliomas and a majority of sec-
ondary glioblastomas (GBMs) [1–3]. Glioma patients, 
whose lesions harbor IDH mutations are associated with 
better prognosis, are more sensitive to chemo-radiation 
therapy and demonstrate longer survival than those with 
wild-type IDH [4, 5]. These mis-sense mutations may 
confer the neomorphic ability to reduce isocitrate dehy-
drogenase, resulting in the accumulation of the “oncome-
tabolite” 2-hydroxyglutarate (2HG) [6, 7] rather than its 
normal catalysis into α-ketoglutarate. IDH-mutation sta-
tus has taken on greater clinical significance in this era of 
molecular diagnostics, with recent major restructuring of 
central nervous system (CNS) tumors as published in the 
2016 WHO classification [8].
In addition to 2HG, several other metabolic processes 
are altered in brain tumors. A prominent resonance from 
total choline comprising of free choline (Cho), phos-
phocholine (PC) and glycerophosphocholine (GPC) is 
commonly observed in conventional 1D proton mag-
netic resonance spectroscopy (1H MRS) studies of brain 
tumors. However, in order to properly understand the 
dysregulated Cho metabolism, it is important to detect 
and quantify relative levels of PC, a vital indicator for the 
expression and/or activity of choline kinase [9] and GPC. 
Also important is to understand the alteration in the glu-
tamate (Glu), glutamine (Gln) and gamma-aminobutyric 
acid (GABA) cycle as Glu is involved in the cellular ana-
bolic pathways and in facilitating tumor invasion [10].
Non-invasive detection of 2HG and other resonances 
on conventional 1H MRS is challenging due to extensive 
overlap with the resonances of neighboring metabo-
lites. Previous 1H MRS studies have employed two dif-
ferent acquisition and processing strategies to resolve 
2HG from overlapping resonances in  vivo. Choi et  al. 
[11, 12]. used a modified chemical-shift imaging (CSI) 
sequence with empirically-optimized pulse timing and a 
prior-knowledge based fitting to detect 2HG [11]. This 
sequence employs an echo time (TE) of 97 ms to detect 
resonances correspond to 2HG, but this comes with the 
limitation that quantification of other metabolites then 
becomes more difficult. A second strategy to detect 2HG 
is to use two-dimensional localized correlated spectros-
copy (2D L-COSY) to introduce a second spectral dimen-
sion and identify 2HG by “cross-peak” resonances due to 
J-coupling interactions [13]. Using in  vivo 2D L-COSY 
[14, 15], Ramadan et al. [16] have reported the detection 
of several metabolites such as PC, GPC, Lac and Glu/Gln 
from GBMs, indicating a potential utility of 2D L-COSY 
in further characterization of brain neoplasms. Though 
well-separated, these cross-peaks show lower signal 
intensity than primary resonances because they origi-
nate only from the small fraction of nuclei which undergo 
coherence transfer during t1-evolution, motivating a 
move to higher field strengths.
The introduction of ultrahigh field (7T) scanners 
improves the sensitivity of 1H MRS in the detection of 
2HG and other complex metabolites due to greater sig-
nal to noise ratio and increased chemical shift dispersion. 
We have recently implemented 2D L-COSY at 7T [17], to 
reliably identify metabolites that were otherwise difficult 
to resolve with conventional 1H MRS, especially at lower 
field strength [11]. In this study, we aimed to test the effi-
cacy of 2D L-COSY at 7T for detection of 2HG in IDH-
mutated gliomas.
Methods
Subjects
The study was approved by the Institutional Review 
Board of the University of Pennsylvania and is compliant 
with the Health Insurance Portability and Accountabil-
ity Act. Written informed consent was obtained from all 
patients prior to the study. A total of nine patients (five 
female, four male, ages 18–72  years, mean  =  42  years) 
with suspected intracranial neoplasms based on clinical 
presentation and routine 3T MR imaging findings were 
recruited for this study. All 7T scans were performed 
following initial diagnosis and prior to surgical biopsy/
tumor resection and chemo-radiation therapy. Histo-
pathological and immunohistochemical analyses on the 
resected tumor specimens were subsequently performed 
and the findings were compared with the results from 
spectral data, specifically for tumor grade and IDH muta-
tion status.
MR imaging and spectroscopy
All scans were performed on a Siemens (Siemens Health-
care, Erlangen, Germany) 7T MRI/MRS whole-body 
scanner equipped with a 32-channel transmit/receive 
head coil. Axial T2-weighted fluid-attenuated inver-
sion recovery (FLAIR) imaging was used to facilitate 
voxel localization on the intracranial neoplasms. Imag-
ing parameters for the FLAIR sequence included: Echo 
time (TE)  =  382  ms, repetition time (TR)  =  4500  ms, 
TI  =  2150  ms, 1 average, 240  ×  240  mm2 field 
of view (FOV), 320x320 matrix size, 208 slices, 
0.8 × 0.8 × 0.8 mm3 resolution, 6 min scan time.
A single voxel 2D L-COSY sequence was performed 
by selecting a voxel size of 8.8–18.0  ml from the solid 
portion of the neoplasm, carefully avoiding regions of 
hemorrhage/cysts. 2D L-COSY scan parameters were as 
follows: TE = 20 ms, TR = 2000 ms, 8 averages for each 
incremental period, 64 ∆t1 increments of 0.4 ms, 2048 t2 
points with F2/F1 bandwidth = 4000/2500 Hz with a total 
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scan time of 17  min. B1 field optimization was assisted 
by the automated FASTESTMAP (Siemens Healthcare) 
algorithm and water suppression was performed using 
the variable power and optimized relaxation delays 
(VAPOR) module [18].
Spectra from neoplasms were compared with data 
obtained from six healthy controls as part of a previous 
study [19]. In that study a voxel size of 27.0  ml encom-
passing bilateral cortical occipital region was used in all 
subjects. All other scan parameters for the control sub-
jects were identical to those for the patients.
Data processing
Data from the 2D L-COSY studies were reconstructed 
offline using a custom MATLAB-based reconstruction 
program. Post-processing steps included Fourier trans-
form, zero-filling, apodization using a squared shifted 
sine-bell windowing function and combining coil and 
averaging data. Metabolite signals were quantified 
through peak volume integration. The diagonal reso-
nance of creatine (Cr) at [F2, F1] = 3.0, 3.0 ppm was used 
as an internal reference for computing metabolite ratios. 
Chemical shifts were calibrated using the resonance of 
NAA at [F2, F1] =  2.0, 2.0  ppm. Detection of 2HG was 
used to prospectively determine IDH mutation status 
and these findings were subsequently compared with the 
results from pathology.
Determination of IDH Status by Immunohistochemistry
Patient demographics along with histopathological grad-
ing and immuno-histochemical findings are presented 
in Table 1. Of the nine patients, one participant (patient 
#3) expressed physical discomfort during the scan 
and requested to terminate the study prematurely. 2D 
L-COSY data from two other subjects (patients #7 and 
#8, Table 1) had sub-optimal water suppression and pro-
duced spectra of insufficient quality for reliable metabo-
lite quantification. Both of these spectra featured a broad 
resonance due to the residual signal from unsuppressed 
water in the region where the resonances due to 2HG, 
GPC, PC and Lac would be expected.
Tissue specimens received by pathology were fixed in 
formalin and processed for paraffin embedding. Hema-
toxylin and eosin staining and immunohistochemis-
try were conducted on 5-micron thick formalin-fixed, 
paraffin-embedded tissue sections mounted on Leica 
Surgipath slides followed by drying for 60  min at 70°. 
Immunohistochemistry with the anti-IDH1-R132H anti-
body (Monoclonal Mouse Anti-human IDH1 (R132H), 
Dianova, DIA Clone H09) and DAB chromogen was 
performed on a Leica Bond III instrument using Bond 
Polymer Refine Detection System (Leica Microsys-
tems AR9800) following a 20-min heat-induced epitope 
retrieval with Epitope Retrieval 2, EDTA, pH 9.0.
Results
2D L-COSY spectra showed presence of 2HG at [F2, 
F1] = 4.0, 1.7 ppm in two of the six glioma cases (grade III 
anaplastic astrocytoma and grade II diffuse astrocytoma). 
None of wild-type IDH1 patients demonstrated the 2HG 
peak on the 2D L-COSY spectrum. IHC confirmed IDH1 
mutation in both patients whose spectra showed pres-
ence of 2HG and IDH1 mutation was not detected in 
any of the other glial tumors studied. 2D L-COSY spec-
trum from a tumor harboring IDH1 mutation (patient 
#9) is shown in Fig. 1 with the voxel localization for the 
MRS shown on the T2-FLAIR image (inset). The diagonal 
peaks and cross-peak resonances due to coherence trans-
fer in J-coupled metabolites are well-resolved and some 
of them have been labeled as: 2HG, Lac, lipids, GPC, PC, 
GPE  +  PE and mI  +  Cho. Representative 2D L-COSY 
spectrum from a patient with a wild-type IDH1 (patient 
#4) is shown in Fig. 2.
Besides NAA, Cr, tCho and mI that are typically 
resolved on 1D 1H MRS of brain neoplasms, resonances 
corresponding to other metabolites, e.g. PC, GPC, Glu, 
Table 1 Patient demographics and histological diagnosis
ID Age (years) Sex Histopathology results WHO grade IDH1 status Spectral quality
1 45 F Hematoma Not tested Good
2 49 F Metastatic breast primary Not tested Good
3 32 F Low grade glioma (clinical MRI) Not available N/A
4 58 F Ganglioglioma I Wild-type Good
5 43 F Ganglioglioma/xanthoastrocytoma I/II Wild-type Good
6 18 M Diffuse astrocytoma II Mutant Good
7 22 M Astrocytoma II Mutant Poor
8 72 M Anaplastic astrocytoma III Wild-type Poor
9 36 M Anaplastic astrocytoma III Mutant Good
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Gln, Lac and lipids were clearly resolved on 2D L-COSY 
spectra in each of the six patients. In addition, we also 
observed resonances corresponding amino acids such as 
aspartate (Asp) and lysine (Lys) not generally detected on 
1D 1H MRS (Figs. 1, 2).
Figure  3 shows ratios of Lac and tCho with respect 
to creatine in each of the six brain tumor patients and 
normal controls. GPC/Cr and PC/Cr ratios were high 
in the only WHO grade III tumor studied, while these 
ratios were indistinguishable from normal controls in the 
patient with hematoma. An increasing trend in GPC, PC 
and total Cho was noticed with increasing tumor grade. 
No such trend was observed for the Lac signal.
Table  2 shows a list of ratios of cross-peak metabo-
lite resonances with respect to Cr from the six patients 
and six normal subjects. These metabolites included 
Lac, lipids, lysine (Lys), Glu, Gln (and their combined 
resonance, Glx), NAA, Asp, mI, glycerophosphoethan-
olamine (GPE) and phosphoethanolamine (PE), the com-
bined cross peaks of mI and free choline (mI  +  Cho), 
GPC and PC.
Discussion
To our knowledge, this is the first study of its kind in 
which 2D L-COSY has been used to characterize brain 
tumors at ultrahigh fields. The proportionately higher 
spectral separation on the 7T scanner improved specific-
ity of detection of 2HG as well as other highly relevant 
metabolites in tumors, such as GPC, PC, Lac, Lys, Glu 
and Gln that are difficult to unambiguously resolve at 
lower fields.
Previous studies have reported that over 50 % of WHO 
Grade II/III gliomas harbor IDH mutations [1, 2]. In fact, 
the 2016 update to the WHO Classification of Tumors 
of the CNS has made this molecular change part of the 
diagnosis for the grade II/III “diffuse astrocytoma, IDH-
mutant,” “anaplastic astrocytoma, IDH-mutant,” “oligo-
dendroglioma, IDH-mutant and 1p/19q-codeleted” and 
“anaplastic oligodendroglioma, IDH-mutant and 1p/19q-
codeleted.” Grade II “diffuse astrocytoma, IDH-wildtype” 
is a provisional entity given its rarity [8]. 2HG has been 
considered as a putative biomarker of these genotypes. A 
previous study [20] reported that patients with gliomas 
bearing IDH mutations show better response to chemo-
radiation therapy and thus present favorable clinical out-
come corroborating the need for 2HG detection to guide 
clinical management [20–23]. These mutations may also 
be candidates for targeted therapy (e.g. AGIOS 121) [24], 
making reliable detection of IDH mutation increasingly 
relevant to both the selection and monitoring of treat-
ment efficacy, providing real-time feedback as a robust 
biomarker. Although IDH mutations can be identified 
by immunohistochemical analysis of resected tumor 
specimens [25–27], non-invasive detection of 2HG lev-
els using 1H MRS techniques can be used to monitor 
Fig. 1 7T COSY spectrum from an 11.0 ml voxel localized within 
a patient with mutant-IDH1 WHO grade III anaplastic astrocytoma 
(middle inset). Metabolite peaks including the resonance peak due to 
2HG have been labeled. The cross peaks from 2HG at [F2, F1] = 4.0, 
1.7 ppm are identified within the red box
Fig. 2 7T COSY spectrum from an 8.8 ml voxel localized in a patient 
with wild-type IDH1 WHO grade 1 ganglioglioma (middle inset) 
showing absence of cross peaks from 2HG (empty red box around [F2, 
F1] = 4.0, 1.7 ppm)
Page 5 of 8Verma et al. J Transl Med  (2016) 14:274 
targeted therapy. Detection of these biomarkers with 
7T 2D L-COSY may inform the decision for change in 
therapy.
We observed 2HG in each of the two patients with 
gliomas bearing IDH mutation and in none of the four 
wild-type tumors, thus substantiating the usefulness of 
7T 2D L-COSY in resolving the complex signals of 2HG 
overlapping with other metabolites. 1D 1H MRS studies 
have recently demonstrated [5, 11, 13, 28–31] in  vivo 
detection of 2HG in patients with gliomas harboring IDH 
mutation. These published studies have typically been 
performed on clinical 3T scanners and relied on modi-
fied sequences with optimized echo-timing to resolve 
complex resonances of 2HG from Glu, Gln and GABA. 
This may limit the signal quality from other metabolites 
and thus confound their reliable quantification. Both of 
Fig. 3 Metabolite/Cr ratios for Lac, Cho, PC and GPC measured in L-COSY data from each of the six patients (red) and six controls (blue)
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the 7T 1D MRS reporting 2HG utilized relatively long 
TEs (78 and 110 ms) for the purposes of signal optimiza-
tion [12, 31], which may again limit assessment of short-
T2 metabolites like Glu and Gln, particularly at such high 
field. It appears that 2D L-COSY represents an alterna-
tive technique for unambiguously detecting 2HG while 
simultaneously identifying additional clinically-relevant 
metabolites with high sensitivity.
In tumors, elevated total Cho levels, detected by 1H 
MRS, is indicative of increased cell membrane turno-
ver and tumor malignancy [32, 33]. Moreover, relative 
amounts of PC and GPC have been suggestive of markers 
for predicting tumor grade [34] using in  vitro 1H MRS. 
In an in  vitro 1H MRS study of tumor extracts [34], it 
was reported that PC was the predominant total choline 
(tCho) peak in high grade gliomas, while GPC dominates 
in low grade gliomas and normal brain. The higher PC in 
high grade gliomas has been attributed to higher expres-
sion and/or activity of choline kinase, phospholipase C 
and Cho transporters that have been exploited as poten-
tial targets for therapy [35]. Furthermore, alterations in 
the PC/GPC ratio have been proposed as a marker of 
malignant transformation and treatment response [36]. 
Taken together, these studies provide adequate impetus 
to separate PC from GPC in vivo, to study tumor phos-
pholipid metabolism, which can be studied using the 2D 
L-COSY technique as demonstrated in this study.
Detection of elevated Lac in neoplasms in our study is 
consistent with previous studies [37–39] and may reflect 
elevated tumor glycolysis and/or poor tissue perfusion. 
However, reliable detection of Lac on 1D 1H MRS is 
problematic due to presence of intense co-resonant lipids 
signals that are also elevated in brain neoplasms [40] and 
may also be present as an artifact from skull, as seen in 
patient #4 (Fig.  2). 2D L-COSY facilitates separation of 
Lac from background lipid signals through detection of 
the Lac cross-peak.
Brain neoplasms exploit Glx transporter expression 
and function to alter Glu-Gln homeostasis, which sup-
ports their growth, invasion, and survival [41]. Closely 
coupled to Glx, the role of GABA has also been studied 
in brain neoplasms [42, 43]. Consequently, reliable detec-
tion of these metabolites is valuable for studying tumor 
metabolism. In the present study, cross-peaks of Glu, Gln 
and GABA were clearly observed which may aid in better 
understanding of the tumor metabolism.
Spectral acquisition methods such as multiple quan-
tum filtered spectroscopy and spectral editing techniques 
Table 2 Metabolite ratios with respect to Cr in patients and normal controls from the L-COSY data
The first five rows represent data from resonances that appear as diagonal peaks (indicated by -d)
ND not detected
Metabolites (Cr) Chemical shift Patient 1 Patient 2 Patient 4 Patient 5 Patient 6 Patient 9 Controls (N = 6)
F2 (ppm) F1 (ppm) N/A N/A Grade I Grade I/II Grade II Grade III N/A
NAA-d 2.0 2.0 1.80 1.29 1.49 1.06 1.29 1.21 1.37
Cr-d 3.0 3.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Cho-d 3.2 3.2 0.72 0.99 0.86 1.05 0.81 1.81 0.64
mI-d 3.5 3.5 0.36 0.38 0.38 0.68 0.45 0.82 0.28
Lipid-d 0.9 1.3 0.78 1.67 1.09 0.91 0.59 1.25 ND
Lac 4.1 1.3 0.05 0.09 0.14 0.06 0.04 0.10 0.01
Lys 3.0 1.7 0.14 0.12 0.16 0.11 0.12 0.11 0.10
GABA 3.0 1.9 0.10 0.08 0.15 0.11 0.08 0.08 0.07
Glu 2.4 2.0 0.21 0.23 0.21 0.20 0.24 0.19 0.23
Gln 2.5 2.1 0.19 0.39 0.19 0.19 0.21 0.26 0.20
Glx 3.7 2.1 0.09 0.15 0.09 0.11 0.11 0.14 0.17
NAA 4.4 2.5 0.05 0.03 0.04 0.02 0.04 0.03 0.05
Asp 3.9 2.8 0.03 0.04 0.05 0.07 0.05 0.07 0.05
Tau 3.4 3.2 0.14 0.12 0.16 0.12 0.08 0.19 0.09
mI 3.6 3.3 0.23 0.24 0.31 0.30 0.30 0.53 0.24
GPE/PE 3.9 3.2 0.04 0.06 0.04 0.06 0.13 0.11 0.04
2HG 4.0 1.7 ND ND ND ND 0.08 0.10 ND
mI + Cho 4.1 3.3 0.04 0.06 0.04 0.05 0.07 0.08 0.06
PC 4.2 3.6 0.04 0.06 0.06 0.07 0.08 0.12 0.07
GPC 4.3 3.7 0.02 0.05 0.05 0.07 0.07 0.13 0.04
GSH 4.5 2.9 0.03 0.04 0.04 0.07 0.04 0.05 0.03
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have been used to unravel potentially overlapping reso-
nances [44]. However, technical restrictions associated 
with these sequences such as sensitivity to motion arti-
facts and constraint of observing only a single metabolite 
at a time render these techniques less attractive to study 
brain neoplasms in  vivo [44]. On the other hand, 2D 
L-COSY provides improved signal, better dispersion of 
J-coupled peaks and detection of multiple metabolites in 
a single recording [15]. 2D L-COSY at 7T unambiguously 
resolved many overlapping resonances with improved sig-
nal and better chemical shift dispersion compared to 1D 
MRS or studies at lower field strengths [19] suggesting 
the increased sensitivity of ultra-high field 2D L-COSY in 
studying brain neoplasms as shown in this study.
This study was limited in sample size and by heteroge-
neity of tumor types primarily because the purpose was 
simply to demonstrate the feasibility of the sequence in 
assessing brain tumor metabolism and detecting 2HG. 
Follow-up studies are needed to focus on metabolic dif-
ferences in specific tumor types. We acknowledge the 
limitations of our 2D-LCOSY technique with respect to 
1D MRS in terms of relatively longer acquisition time. 
Future modifications of this sequence would benefit from 
acceleration techniques like matched accumulation [45] 
or sparse sampling to reduce overall scan time. Metabo-
lite quantification of resonances detected in 2D L-COSY 
could also be improved by implementing a prior-knowl-
edge based fitting approach analogous to LCModel 
[46] fitting on 1D MRS rather than the peak integration 
method that was used in the present study. ProFit [47] 
is one such 2D prior-knowledge based fitting algorithm, 
and adopting this program to 7T studies could improve 
the metabolite quantification.
Conclusion
We have demonstrated that 2D L-COSY has the ability 
to detect 2HG in vivo which has significant translational 
implications. We believe that 2D L-COSY may further 
improve our understanding of tumor physiology and 
metabolism and thus assist in better characterizing brain 
tumor genotypes in an era of molecular diagnostics and 
personalized medicine. As targeted therapies are devel-
oped for the IDH pathway, 2D-L-COSY could be used to 
detect 2HG as a key biomarker to evaluate treatment effi-
cacy in a dynamic, iterative, real-time fashion, optimizing 
clinical trials and patient outcomes.
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